Analysts/Institutional Investor Meet/Con. Call Updates

August 13, 2026 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Phiroz Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (E), 25th floor, Dalal Street, MUMBAI -400 051 MUMBAI -400 001 Company Code No. AUROPHARMA Company Code No. 524804 Dear Sir / Madam, Sub: Transcript of Q1FY27 earnings call. Please refer to our letter dated July 29, 2026, wherein we intimated the schedule of Earnings call on August 6, 2026. We are attaching herewith the transcript of the said earnings call on the Unaudited Financial Results of the Company for the first quarter ended June 30, 2026 and the same is being uploaded on the website of the Company and is available at the following web link. https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/conference-call- transcripts/ Please take the information on record. Thanking you, Yours faithfully, For AUROBINDO PHARMA LIMITED B. Adi Reddy Company Secretary Encl.: as above Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana, India Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com Q1 FY27 Earnings Conference Call August 06, 2026 Dr. Satakarni Makkapati – CEO of Aurobindo Biosimilars, Vaccines and Peptide Businesses & Director of Aurobindo Pharma Limited Mr. Yugandhar Puvvala – CEO of Eugia Pharma Specialties Limited Mr. Swami Iyer - CEO, Aurobindo Pharma, USA Mr. V. Muralidharan – CEO, Europe Formulations Business Mr. S. Subramanian - CFO, Aurobindo Pharma Limited Mr. Varun Mali – Investor Relations and Corporate Communications Team Aurobindo Pharma Limited 06 August 2026 Vandit Jaswani: Ladies and gentlemen, good day and welcome to Aurobindo Pharma's Earnings Conference Call for first quarter of FY27. Please note, all participants' lines will be in ‘listen-only’ mode and there will be an opportunity for you to ask questions after management's opening remarks. Should you need any assistance during the conference call, please raise your hand from the participant tab on the screen. Please note, this conference is being recorded. I now hand over the conference to Mr. Varun Mali. Thank you and over to you, sir. Varun Mali: Thank you, Vandit. Good morning, ladies and gentlemen, and welcome to our first quarter FY27 Earnings Call. I am Varun Mali from the Investor Relations and Corporate Communications team. We hope you have received the Q1 FY27 financials and the press release that was sent out yesterday. These are also available on our website, www.aurobindo.com. I would now like to introduce our senior management team who is on the call with us today, represented by: • Dr. Satakarni Makkapati – CEO, Aurobindo Biosimilars, Vaccines & Peptides Businesses and Director - Aurobindo Pharma Limited. • Mr. Yugandhar Puvvala - CEO, Eugia Pharma Specialities Limited. • Mr. Swami Iyer - CEO, Aurobindo Pharma, USA. • Mr. V. Muralidharan - CEO, Europe Formulations Business. • Mr. S. Subramanian - CFO, Aurobindo Pharma Limited. We will begin the call with the summary highlights from the management, followed by an interactive Q&A session. Please note that some of the matters we will discuss today are forward-looking, including and without limitations, statements relating to the implementation of strategic actions and other affirmations on our future business, business development and commercial performance. While these forward-looking statements exemplify our judgement and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors may cause actual developments and results to vary materially from our expectations. Aurobindo Pharma undertakes no obligation to publicly revise any forward-looking statements to reflect in future events or circumstances. With that, I will now hand over the call to our CFO for the business highlights of this quarter. Over to you, sir. S. Subramanian: Good morning, everyone. A warm welcome to Aurobindo Pharma's Q1 FY27 Earnings Call. Thank you for taking the time to join us today to discuss the company's financial and operational performance of the first quarter of the current fiscal year. Q1 marked another quarter of disciplined execution underpinned by strong operating performance, continued strategic progress and prudent capital allocation. Our diversified business model continues to perform well despite geopolitical issues positioning us for sustainable long-term value creation. Aurobindo Pharma Limited 06 August 2026 • Our consolidated revenues increased by 16% year-on-year to Rs. 9,150 crores driven by broad-based performance across our business area. • European growth market maintained strong momentum and our U.S. business contained a sustained growth. • Operating EBITDA, exploring one-time impact of Rs. 43 crores towards a loss on derecognition of leased residuals, stood at Rs. 1,924 crores with a margin of 21%. A defining milestone during the quarter was the successful completion of the Lannett acquisition following FTC approval within the stipulated timelines. Beyond adding scale, the acquisition strengthens our U.S. platform, expands our presence in complex and controlled substances, and enhances our long-term competitive position. Further production at our China OSD facility doubled over past 12 months, making a significant milestone in the ramp-up of one of our strategic investments for sustained growth. We are pleased to report an increase in supply from China to Europe and also to the U.S. starting now. Business highlights: Let me walk you through the key business highlights for the quarter. • Our formulation business remained a primary growth driver, growing 17% year-on- year to Rs. 8,101 crores and contributing approximately 89% of the consolidated revenues, supported by growth across all key markets. • API business clocked revenue Rs. 1,049 crores accounting for 11% of the overall revenues supported by our backward integration strategy. • U.S. revenues grew by 8.1% year-on-year to Rs. 3,770 crores or $399 million reflecting the resilience of our base business. We launched 10 new products this quarter. Filed 9 ANDAs, received 10 final approvals, indicating strong pipeline execution and regulatory momentum. • Our European business continued its strong trajectory with revenues reaching €267 million, delivering 11% year-on-year growth in constant currency terms. • Growth markets revenues increased by 38% year-on-year to Rs. 1,063 crores or $113 million, supported by strong underlying performance across key markets. • ARV formulation remained stable at $35 million for the quarter, driven by stable volume. • Our biosimilar and biological CMO strategy continues to progress well and represent important long-term growth drivers along our base business. Aurobindo Pharma Limited 06 August 2026 Operational and Financial highlights: Gross margin remained resilient at 60.4% compared to 58.8% of Q1 FY26, benefiting from an improved business mix and operating efficiency. Our gross contribution amounted to Rs. 5,523 crores. Net CapEx for the quarter stood at $78 million. Capital expenditure remained focused mainly towards TheraNym Biologics. R&D expenses for the quarter is around Rs. 350 crores, amounting to 4% of the revenues. We expect the current rate to continue, driven by research costs towards the pipeline and the higher base of revenues. Further, since multiple clinical studies are at an advanced stage, we expect slightly lower development costs for the upcoming period. Our balance sheet continues to remain strong with a strong net cash position of $42 million after payment of $85 million towards buyback and $247 million [Showing first 8,000 characters — download PDF for full document]